SABR controls oligometastatic breast lesions well, but systemic benefit remains uncertain
SABR achieved 92.5% one-year local control in oligometastatic breast cancer, while pooled randomized evidence did not definitively establish a PFS benefit.
Tag
oligometastatic
SBRT is moving beyond palliation in oligometastatic pancreatic cancer
SBRT can provide high local control in selected oligometastatic pancreatic cancer, but randomized survival evidence and patient-selection criteria remain limited.
SBRT plus dual checkpoint blockade produced 72.7% six-month PFS in oligometastatic HNSCC
Durvalumab, tremelimumab and SBRT produced 72.7% six-month progression-free survival in 33 patients with oligometastatic HNSCC.
Oligometastatic survivorship is outgrowing traditional oncology follow-up models
Longer survival after metastasis-directed therapy is creating unmet physical, psychological and functional needs that conventional surveillance pathways may not adequately address.
SBRT controlled bone lesions but rarely delayed systemic therapy in bladder cancer
Two-year local control reached 88%, but median progression-free survival was 5.8 months and systemic treatment changed after 4.4 months.